The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita Announces Shareholder Approval of Corporate Split and New…

- Both companies will be independently listed on the Warsaw Stock Exchange with formal completion of the split expected in...
More

Selvita Announces First Patient Dosed in Phase 1b Study…

Krakow, Poland – 06 September 2019 – Selvita (WSE: SLV) today announced that the first patient enrolled in the Phase...
More

Selvita Reports Second Quarter and Half-Year 2019 Financial Results

Krakow, Poland – 5 September 2019 – Selvita (WSE:SLV) today reported second quarter 2019 financial results and provided a corporate...
More

Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing…

- Shareholder meeting to be held Sept. 19, 2019, for a vote on the split, name of Ryvu Therapeutics for...
More

Selvita to Present at Upcoming Conferences in September

Krakow, Poland – 3 September 2019 – Selvita (WSE: SLV) today announced that Pawel Przewiezlikowski, Chief Executive Officer, will present...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV 0,2000 PLN ( 0,33% )

Share price 2019-09-20 17:00:00

60,2000 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More